To devise an intensified treatment regimen for patients with advanced, resectable head and neck squamous cell carcinomas.
Phase I/II clinical trial consisting of perioperative cisplatin chemoradiotherapy, surgical resection, intraoperative radiotherapy, and postoperative cisplatin chemoradiotherapy.
The Ohio State University Comprehensive Cancer Center, Columbus.
Thirty-seven patients (median age, 63 years) with advanced oral cavity, oropharyngeal, or hypopharyngeal carcinomas.
The range of time at risk was 1 to 30 months (median, 21 months). Thirty of the 37 registered patients were analyzable; 11 have died (5 with distant metastases; 1 of lung carcinoma; and 5 were cancer-free); 2 experienced second primary tumors in the oral cavity (out of or adjacent to the previous radiotherapy portals). Treatment compliance was excellent (92%), morbidity was low, and excellent locoregional control was achieved.
The initial results are encouraging; the future strategy will intensify the systemic component of therapy based on results from concurrent laboratory studies.Arch Otolaryngol Head Neck Surg. 1997;123:139-144
Schuller DE, Grecula JC, Gahbauer RA, et al. Intensified Regimen for Advanced Head and Neck Squamous Cell Carcinomas. Arch Otolaryngol Head Neck Surg. 1997;123(2):139–144. doi:10.1001/archotol.1997.01900020013002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: